Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × FED × Neoplasm Metastasis × Clear all

Phase

Phase 2 3 Phase 1 2 Phase 2/3 1

Status

Sponsor Class

OTHER 29 INDUSTRY 18 OTHER_GOV 1 NETWORK 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3 Uterine Cervical Dysplasia 1 Ototoxicity 1 Neoplasm Metastasis 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Health Education 1 Colorectal Neoplasms 1 Bowen's Disease 1

Interventions

relugolix 1 nilutamide 1 histrelin 1 enzalutamide 1 bicalutamide 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 Triptorelin Pamoate 1 Prednisone 1 Methylprednisolone 1 Leuprolide 1 Goserelin 1 Flutamide 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡